Budi Permana

Dr. Budi Permana

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2023 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
BPBudi Permana
Budi Permana
SBScott Beatson
Scott Beatson
BFBrian M. Forde
Brian M. Forde
Background: Cluster and transmission analysis utilising pairwise SNP distance are increasingly used in genomic epidemiological studies. However, current methods are often challenging to install and use, and lack interactive functionalities for easy data exploration. Results: GraphSNP is an interactive visualisation tool running in a web browser that allows users to rapidly generate pairwise SNP distance networks, investigate SNP distance distributions, identify clusters of related organisms, and reconstruct transmission routes. The functionality of GraphSNP is demonstrated using examples from recent multi-drug resistant bacterial outbreaks in healthcare settings. Conclusions: GraphSNP is freely available at https://github.com/nalarbp/graphsnp. An online version of GraphSNP, including demonstration datasets, input templates, and quick start guide is available for use at https://graphsnp.fordelab.com.

15 June 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
BPBudi Permana
Budi Permana
PHPatrick Harris
Patrick Harris
NRNaomi Runnegar
Naomi Runnegar
MLMargaret Lindsay
Margaret Lindsay
BHBelinda C. Henderson
Belinda C. Henderson
BFBrian M. Forde
Brian M. Forde
Vancomycin-resistant Enterococcus faecium (VREfm) is a leading cause of health care-associated infections (HAIs) globally. In Australia, the spread of hospital-adapted VREfm is largely driven by a single clonal group (clonal complex [CC]), CC17, to which the lineage ST78 belongs.

15 July 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
IGIan Gassiep
Ian Gassiep
MCMark D. Chatfield
Mark D. Chatfield
BPBudi Permana
Budi Permana
DBDelaney Burnard
Delaney Burnard
MBMichelle J. Bauer
Michelle J. Bauer
PHPatrick Harris
Patrick Harris
Background: Burkholderia pseudomallei, the causative agent of melioidosis, is highly genetically recombinant, resulting in significant genomic diversity. Multiple virulence factors have been associated with specific disease presentations. To date, there are limited data relating to genomic diversity and virulence factors associated with melioidosis cases in North Queensland, Australia. Aim: To describe the genetic diversity of B. pseudomallei and identify virulence factors associated with clinical risk factors and patient outcomes. Methods: Whole genome sequencing of clinical isolates was performed and analysed with clinical data obtained from a retrospective melioidosis cohort study. Results: Fifty-nine distinct sequence types (STs) were identified from the 128 clinical isolates. Six STs comprised 64/128 (50%) isolates. Novel STs accounted for 38/59 (64%) STs, with ST TSV-13 as the most prevalent (n = 7), and were less likely to possess an LPS A genotype or YLF gene cluster (p < 0.001). These isolates were most likely to be found outside the inner city (aOR: 4.0, 95% CI: 1.7–9.0, p = 0.001). ST TSV-13 was associated with increased mortality (aOR: 6.1, 95% CI: 1.2–30.9, p = 0.03). Patients with a history of alcohol excess were less likely to be infected by fhaB3 (aOR 0.2, 95% CI: 0.1–0.7, p = 0.01) or YLF (aOR: 0.4, 95% CI: 0.2–0.9, p = 0.04) positive isolates. Conclusions: There are a significant number of novel sequence types in Townsville, Australia. An emerging novel ST appears to have an association with geographic location and mortality. Ongoing investigation is required to further understand the impact of this ST on the Townsville region.

13 July 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
YWYalew Wale
Yalew Wale
JRJason Roberts
Jason Roberts
HWHayoung Won
Hayoung Won
SRSheethal Reghu
Sheethal Reghu
DMDusan Marjanovic
Dusan Marjanovic
FSFekade Sime
Fekade Sime
Aminoglycosides are commonly partnered with β-lactam antibiotics for empirical treatment of severe Gram-negative bacterial infections, including those caused by Pseudomonas aeruginosa. However, the optimal duration of aminoglycoside therapy when co-administered with β-lactam antibiotics remains poorly defined. This study compared the antibacterial efficacy of short (one-day, three-day) versus long course (seven-day) of tobramycin therapy, co-administered with piperacillin/tazobactam, against piperacillin/tazobactam-resistant clinical isolates of P. aeruginosa in a hollow fibre infection model (HFIM). A broth microdilution method was used to determine the minimum inhibitory concentration (MIC) of the antibiotics. The HFIM experiments were performed using two piperacillin/tazobactam-resistant clinical isolates, CTAP-32 and CTAP-72 (both with piperacillin/tazobactam MICs > 128 mg/L). The clinical dose of tobramycin (10 mg/kg/day IV) was simulated for one, three, and seven days, each in combination with piperacillin/tazobactam (4.5 g every six hours infused over 30 min). In the HFIM, the one-day, three-day, and seven-day courses of tobramycin administered with piperacillin/tazobactam resulted in comparable bacterial kill with ~3log10 CFU/mL bacterial density reduction within the first 8 h of treatment against the CTAP-32 bacterial isolate. Similarly, these three combination regimens resulted in equivalent bacterial killing effects against the CTAP-72 isolate with a ~5log10 CFU/mL bacterial reduction during the initial treatment period. However, despite this early decline, comparable bacterial regrowth was observed thereafter with the short versus the long course of tobramycin co-administered with piperacillin/tazobactam. In conclusion, short-course and long-course tobramycin therapy, when combined with piperacillin/tazobactam, achieved comparable antibacterial efficacy against P. aeruginosa isolates in the HFIM. However, these findings warrant further validation in clinical studies.

3 November 2022
Verified
Thesis
Closed access
BPBudi Permana
Budi Permana
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.

16 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
BPBudi Permana
Budi Permana
TCThom P. Cuddihy
Thom P. Cuddihy
BFBrian M. Forde
Brian M. Forde
The increasing complexity and scale of genomics data demand reporting solutions that are both interactive and easy to share. Here, we present SCIFR, a framework for creating self-contained, single-file interactive reports. SCIFR merges template-based flexibility with web app interactivity. Demonstrated with BLITSFR (comparative genomics) and METAXSFR (metagenomics), SCIFR outperforms established frameworks in efficiency and usability. The platform and tools are openly available, enabling next-generation, shareable reporting across diverse applications.